Combined Chemotherapy and Immunotherapy Induction for Screening of Patients with Cervical Esophageal Carcinoma for Subsequent Local Treatment: A New Treatment Paradigm.

IF 3.4 2区 医学 Q2 ONCOLOGY Annals of Surgical Oncology Pub Date : 2024-12-01 Epub Date: 2024-07-26 DOI:10.1245/s10434-024-15843-3
Liang Dai, Ya-Ya Wu, Yan Sun, Rong Yu, Wan-Pu Yan, Yong-Bo Yang, Hong Cheng, Yi-Mei Gao, Bin Zhang, Ke-Neng Chen
{"title":"Combined Chemotherapy and Immunotherapy Induction for Screening of Patients with Cervical Esophageal Carcinoma for Subsequent Local Treatment: A New Treatment Paradigm.","authors":"Liang Dai, Ya-Ya Wu, Yan Sun, Rong Yu, Wan-Pu Yan, Yong-Bo Yang, Hong Cheng, Yi-Mei Gao, Bin Zhang, Ke-Neng Chen","doi":"10.1245/s10434-024-15843-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Definitive chemoradiotherapy is recommended as the primary treatment for cervical esophageal carcinoma (CEC). However, local control rates remain unsatisfactory for some patients. Therefore, in this study, we introduced a new treatment paradigm for individuals with CEC, customizing the choice between subsequent local treatments based on their response to induction chemotherapy and immunotherapy.</p><p><strong>Patients and methods: </strong>Induction treatment comprised two to four cycles of chemotherapy combined with programmed cell death protein 1 (PD-1) inhibitors. Patients achieving complete response (CR) or near CR after induction treatment underwent definitive chemoradiotherapy (dCRT), while those not achieving CR or near CR underwent surgical resection.</p><p><strong>Results: </strong>Among the 40 eligible patients, 14 (35.0%) achieved a CR or near CR after induction treatment. Of the ten patients achieving a CR or near CR, one developed an esophageal fistula after dCRT (10.0%). Among the eight non-CR or non-near CR patients receiving chemoradiotherapy, six developed esophageal fistula (75.0%). Among the 26 patients who did not achieve CR or near CR after induction treatment, the 1-year cancer specific survival (CSS) rates were 93.3% [95% confidence interval (CI) 0.815-1%] for the 18 patients in the surgery group, and 71.4% (95% CI 0.447-1%) for the 8 patients in the chemoradiotherapy group (p = 0.027). The overall laryngeal preservation rate was 85.0% (34/40), with a functional laryngeal preservation rate of 77.5% (31/40).</p><p><strong>Conclusion: </strong>The approach consisting of combined immunotherapy and chemotherapy successfully identified patients who were responding well to induction treatment and who were sensitive to radiotherapy, for chemoradiotherapy; thus, improving laryngeal preservation rates. In addition, it also identified patients with poor responses to induction treatment and radiotherapy, for timely surgery; hence, reducing radiotherapy complications and enhancing survival.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"9298-9309"},"PeriodicalIF":3.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549207/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1245/s10434-024-15843-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Definitive chemoradiotherapy is recommended as the primary treatment for cervical esophageal carcinoma (CEC). However, local control rates remain unsatisfactory for some patients. Therefore, in this study, we introduced a new treatment paradigm for individuals with CEC, customizing the choice between subsequent local treatments based on their response to induction chemotherapy and immunotherapy.

Patients and methods: Induction treatment comprised two to four cycles of chemotherapy combined with programmed cell death protein 1 (PD-1) inhibitors. Patients achieving complete response (CR) or near CR after induction treatment underwent definitive chemoradiotherapy (dCRT), while those not achieving CR or near CR underwent surgical resection.

Results: Among the 40 eligible patients, 14 (35.0%) achieved a CR or near CR after induction treatment. Of the ten patients achieving a CR or near CR, one developed an esophageal fistula after dCRT (10.0%). Among the eight non-CR or non-near CR patients receiving chemoradiotherapy, six developed esophageal fistula (75.0%). Among the 26 patients who did not achieve CR or near CR after induction treatment, the 1-year cancer specific survival (CSS) rates were 93.3% [95% confidence interval (CI) 0.815-1%] for the 18 patients in the surgery group, and 71.4% (95% CI 0.447-1%) for the 8 patients in the chemoradiotherapy group (p = 0.027). The overall laryngeal preservation rate was 85.0% (34/40), with a functional laryngeal preservation rate of 77.5% (31/40).

Conclusion: The approach consisting of combined immunotherapy and chemotherapy successfully identified patients who were responding well to induction treatment and who were sensitive to radiotherapy, for chemoradiotherapy; thus, improving laryngeal preservation rates. In addition, it also identified patients with poor responses to induction treatment and radiotherapy, for timely surgery; hence, reducing radiotherapy complications and enhancing survival.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
联合化疗和免疫疗法诱导用于筛查宫颈食管癌患者以便进行后续局部治疗:一种新的治疗范例
背景:宫颈食管癌(CEC)的主要治疗方法推荐采用确定性化放疗。然而,部分患者的局部控制率仍不尽如人意。因此,在这项研究中,我们为CEC患者引入了一种新的治疗模式,根据患者对诱导化疗和免疫疗法的反应,定制后续局部治疗的选择:诱导治疗包括两到四个周期的化疗,并结合程序性细胞死亡蛋白1(PD-1)抑制剂。诱导治疗后获得完全应答(CR)或接近CR的患者接受确定性放化疗(dCRT),而未获得CR或接近CR的患者接受手术切除:在40名符合条件的患者中,14人(35.0%)在诱导治疗后达到CR或接近CR。在获得 CR 或接近 CR 的 10 例患者中,有 1 例在 dCRT 后出现食管瘘(10.0%)。在接受放化疗的 8 名非 CR 或非接近 CR 患者中,有 6 人出现食管瘘(75.0%)。在接受诱导治疗后未达到 CR 或接近 CR 的 26 名患者中,手术组 18 名患者的 1 年癌症特异性生存率 (CSS) 为 93.3% [95% 置信区间 (CI) 0.815-1%],化放疗组 8 名患者的 1 年癌症特异性生存率 (CSS) 为 71.4% (95% CI 0.447-1%)(P = 0.027)。总的喉保留率为85.0%(34/40),喉功能保留率为77.5%(31/40):结论:联合免疫疗法和化疗的方法成功地将对诱导治疗反应良好且对放疗敏感的患者确定为化疗患者,从而提高了喉保留率。此外,它还能识别出对诱导治疗和放疗反应不佳的患者,以便及时进行手术,从而减少放疗并发症,提高生存率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.90
自引率
10.80%
发文量
1698
审稿时长
2.8 months
期刊介绍: The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.
期刊最新文献
Correction: The Top Ten Annals of Surgical Oncology Original Articles on Twitter/X: 2020-2023. Correction: ASO Author Reflections: Minimally Invasive Surgery, Three-Dimensional (3D) Reconstruction and Indocyanine Green Fluorescence: The Perfect Combo to Enter the Era of Intraoperative Liver Navigation. Correction: Patient-Reported Outcomes 10 Years After Breast-Conserving Surgery for Early-Stage Breast Cancer. ASO Visual Abstract: Evaluating the Efficacy of Different Treatment Intensities in Nasopharyngeal Carcinoma Patients: A Nationwide Cancer Registry-Based Study. ASO Visual Abstract: Cost-Analysis of Pelvic Exenteration Surgery for Advanced Pelvic Malignancy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1